Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Foolish Forecast: J&J Trudges Along

Is Johnson & Johnson (NYSE: JNJ  ) a recovery story waiting to happen, or still stuck in a rut? We'll get a closer look tomorrow, when the company releases second-quarter results. But until then, here's your sneak peek at what to expect.

What analysts say:

  • Buy, sell, or waffle? With 13 buys, three undecideds, and one analyst giving a thumbs-down, the general sentiment on Wall Street is that Johnson & Johnson shares fetch appealingly low prices right now.
  • Revenue. Analysts are looking for the top line to come in at $16 billion this quarter -- respectable 5.8% growth over the year-ago quarter.
  • Earnings. The bottom-line growth is expected to come in a little higher, at 6.7% or $1.12 per share.

What management says:
Management thinks its stock is cheap. Or so it would seem, from the more than $5 billion in stock Johnson & Johnson repurchased between August 2007 and last quarter's earnings announcement. There's almost $5 billion still available for management to play with, so it'll be interesting to see how much of it Johnson & Johnson used this past quarter, with its stock trading generally higher over the last three months.

What management does:
With a company as large as Johnson & Johnson, margins don't jump around all that much. It really takes a serious improvement in one segment to drive margins.

The one worrisome number is free cash flow, which has been headed in the wrong direction over the last two quarters. Half a year doesn't make a trend -- especially for something as choppy as free cash flow -- but it's certainly something investors should watch.




































All data courtesy of Capital IQ, a division of Standard & Poor's. Data reflects trailing-12-month performance for the quarters ended in the named months.

One Fool says:
Johnson & Johnson is a survivor. It's been able to increase earnings even in the face of the problems that it and Amgen (Nasdaq: AMGN  ) have had with their anemia drugs, as well as continuing safety issues with drug-eluting stents. That latter market won't get any easier, either, with new competition from Medtronic (NYSE: MDT  ) , plus Abbott Labs (NYSE: ABT  ) and Boston Scientific (NYSE: BSX  ) .

While Johnson & Johnson hasn't been firing on all cylinders, other areas have seen enough growth to keep it afloat. The integration of Pfizer's (NYSE: PFE  ) consumer health-care division seems to be proceeding nicely, and adding over-the-counter Zyrtec to the mix has certainly helped. Anti-inflammatory Remicade saw a nice 37% increase in sales last quarter -- thanks in large part to international marketing partner Schering-Plough's (NYSE: SGP  ) contribution of 410% growth year over year.

If Johnson & Johnson can successfully endure a rough patch like this, just imagine how the Motley Fool Income Investor recommendation will do when things turn around.

Johnson & Johnson and Pfizer are Income Investor recommendations. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is also a recommendation of the Inside Value newsletter. The Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 684223, ~/Articles/ArticleHandler.aspx, 10/27/2016 11:00:13 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 hour ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 4:00 PM
JNJ $115.70 Up +1.14 +1.00%
Johnson and Johnso… CAPS Rating: ****
ABT $40.29 Up +0.33 +0.83%
Abbott Laboratorie… CAPS Rating: *****
AMGN $160.57 Up +1.58 +0.99%
Amgen CAPS Rating: ****
BSX $21.49 Down -0.60 -2.72%
Boston Scientific CAPS Rating: ***
MDT $81.13 Up +0.01 +0.01%
Medtronic CAPS Rating: *****
PFE $32.48 Up +0.08 +0.25%
Pfizer CAPS Rating: ****
SGP.DL2 $28.15 Down +0.00 +0.00%
Schering-Plough Co… CAPS Rating: ****